Effects of dopamine agonists on neuropsychiatric symptoms of Parkinson's disease.
The efficacy of dopamine (DA) agonists in the treatment of motor symptoms of Parkinson's disease (PD) has been clearly demonstrated. It has also been documented that DA agonists may have both a positive and a negative impact on neuropsychiatric symptoms in PD patients. This paper will focus on the effects of DA agonists on depressive and cognitive symptoms of PD.
Rektorová
Irena
I
First Department of Neurology, Masaryk University and St. Anne's Hospital, Pekarska 53, CZ-656 91 Brno, Czech Republic. irena.rektorova@fnusa.cz
D000368:Aged; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003863:Depression / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D018491:Dopamine Agonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000150:complications / Q000000981:diagnostic imaging; D011569:Psychiatric Status Rating Scales; D011877:Radionuclide Imaging; D014326:Tropanes / Q000493:pharmacokinetics
D018491:Dopamine Agonists; D007457:Iodine Radioisotopes; D014326:Tropanes; C087552:2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane